September
5, 2006
FDA Postpones Decision on Drug That May Improve Emotional Control in ALS
The Food and Drug Administration
has advised Avanir Pharmaceuticals
(www.avanir.com) that it will delay
making a decision about approval of
Neurodex for emotional lability (uncontrollable
emotions) in amyotrophic lateral
sclerosis (ALS) and other conditions
until Oct. 30.
Neurodex is a combination of dextromethorphan
hydrobromide and quinidine sulfate
that appears to be more effective
than either compound alone in reducing
episodes of undesired emotional expression.
|
| |
|
| |
|
| |
|